- The BOD of BioTime (BTX +1.3%) subsidiary Asterias Biotherapeutics appoints Pedro Lichtinger President and CEO replacing interim chief Dr. Michael D. West. Dr. West will resume his role as VP of Technology Integration and continue to serve as BioTime's President & CEO.
- Mr. Lichtinger was previously President & CEO of Optimer Pharmaceuticals. Prior to that he was an executive at Pfizer (PFE +0.3%). He will earn a base salary of $400K/year and has been granted options to purchase 1M shares of Asterias Biotherapeutics common stock at $2.34 plus 200K shares of restricted Asterias stock under the company's Equity Incentive Plan.
This was corrected on 06/13/2014 at 04:06 PM.
From other sites
at Benzinga.com (Feb 4, 2015)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Dec 20, 2013)
at MarketWatch.com (Jul 13, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs